Page 75 - Read Online

Neumann et al. J Transl Genet Genom 2022;6:353-60 https://dx.doi.org/10.20517/jtgg.2022.06 Page 359

Availability of data and materials
Data regarding the case report can be found on Northwell’s EMR. Data regarding the literature review is
referenced in the manuscript as footnotes and can be found on PubMed.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interes.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Consent for publication has been obtained from the next of kin of the participant.

Copyright
© The Author(s) 2022.

REFERENCES
1. Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol 2009;36:6-7. DOI PubMed
2. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8589.00.pdf [Last accessed on 24 Jun 2022].
3. Jiang J, Ren Y, Xu C, Lin X. NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative
radiotherapy: a case report. Diagn Pathol 2022;17:4. DOI PubMed PMC
4. McEvoy CR, Fox SB, Prall OWJ. Emerging entities in NUTM1-rearranged neoplasms. Genes Chromosomes Cancer 2020;59:375-85.
DOI PubMed
5. Kim YH, Song Y, Kim JK, et al. False-negative errors in next-generation sequencing contribute substantially to inconsistency of
mutation databases. PLoS One 2019;14:e0222535. DOI PubMed PMC
6. Kubonishi I, Takehara N, Iwata J, et al. Novel t(15;19) chromosome abnormality in a thymic carcinoma. Cancer Res 1991;51:3327-8.
PubMed
7. Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer
Res 2012;18:5773-9. DOI PubMed PMC
8. Chau NG, Ma C, Danga K, et al. An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis
(NUT) midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr 2020;4:pkz094. DOI PubMed PMC
9. Available from: https://nmcregistry.org/ [Last accessed on 24 Jun 2022].
10. Huang QW, He LJ, Zheng S, Liu T, Peng BN. An overview of molecular mechanism, clinicopathological factors, and treatment in nut
carcinoma. Biomed Res Int 2019;2019:1018439. DOI PubMed PMC
11. Prall OWJ, Thio N, Yerneni S, Kumar B, McEvoy CR. A NUT carcinoma lacking squamous differentiation and expressing TTF1.
Pathology 2021;53:663-6. DOI PubMed
12. Brägelmann J, Dammert MA, Dietlein F, et al. Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in
NUT midline carcinoma. Cell Rep 2017;20:2833-45. DOI PubMed PMC
13. Han X, Piao L, Zhuang Q, Yuan X, Liu Z, He X. The role of histone lysine methyltransferase NSD3 in cancer. Onco Targets Ther
2018;11:3847-52. DOI PubMed PMC
14. Agaimy A, Tögel L, Stoehr R, et al. NSD3-NUTM1-rearranged carcinoma of the median neck/thyroid bed developing after recent
thyroidectomy for sclerosing mucoepidermoid carcinoma with eosinophilia: report of an extraordinary case. Virchows Arch
2021;479:1095-9. DOI PubMed PMC
15. Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid
cancers. J Clin Invest 2016;126:1052-66. DOI PubMed PMC
16. Zhou J, Duan M, Jiao Q, et al. Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive. IGKV ;11:778296.
DOI PubMed PMC
17. Allison DB, Rueckert J, Cornea V, Lee CY, Dueber J, Bocklage T. Thyroid carcinoma with NSD3::NUTM1 fusion: a case with
thyrocyte differentiation and colloid production. Endocr Pathol 2022;33:315-26. DOI PubMed
18. Chau NG, Hurwitz S, Mitchell CM, et al. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.
Cancer 2016;122:3632-40. DOI PubMed PMC
19. Lim SL, Xu L, Han BC, Shyamsunder P, Chng WJ, Koeffler HP. Multiple myeloma: Combination therapy of BET proteolysis